Shares of Castle Biosciences, Inc. (NASDAQ: CSTL) surged 5.9% in pre-market trading on Monday following the company's strong Q3 2024 earnings release and positive clinical study results for its DecisionDx-Melanoma test.
For the third quarter, Castle Biosciences reported revenue of $85.8 million, up 40% year-over-year, beating analyst estimates by 8.6%. Notably, the company achieved profitability with net income of $2.27 million, compared to a net loss in Q3 2023, and earnings per share of $0.082 exceeding expectations.
The company also raised its full-year 2024 revenue guidance to $320-$330 million from the previous $275-$300 million range, reflecting continued growth momentum.
In addition to the strong financial results, Castle Biosciences presented updated findings from its prospective DECIDE study at the Dermato-Onco2024 conference. The data showed that using the DecisionDx-Melanoma test results to guide clinical decisions resulted in a significant 25% reduction in unnecessary sentinel lymph node biopsy (SLNB) procedures.
Importantly, the study found that no patients with a DecisionDx-Melanoma predicted low risk of less than 5% for lymph node positivity who opted for SLNB had a positive node, supporting the ability of the test to safely identify patients who can avoid the invasive procedure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.